CURRENT ASPECTS OF ETIOTROPIC COVID-19 THERAPY
Since the beginning of the pandemic, repeated attempts have been made to develop etiotropic therapy for a novel coronavirus infection. Hydroxychloroquine, lopinavir/ritonavir, etc. derivatives were used as antiviral agents, however, they demonstrated a low efficiency and an insufficient safety. In t...
Main Authors: | D. N. Zemskov, L. A. Balykova, O. A. Radaeva, K. Ya. Zaslavskaya, P. A. Bely, E. V. Semenova, M. V. Shirmankina, K. N. Koryanova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute
2022-12-01
|
Series: | Фармация и фармакология (Пятигорск) |
Subjects: | |
Online Access: | https://www.pharmpharm.ru/jour/article/view/1194 |
Similar Items
-
MODERN DIRECTED ANTIVIRAL COVID-19 THERAPY: RESULTS OF MULTICENTER CLINICAL EFFECTIVENESS AND SAFETY STUDY OF FIXED NIRMATRELVIR+RITONAVIR COMBINATION
by: L. A. Balykova, et al.
Published: (2022-10-01) -
EFFICACY AND SAFETY OF SOME ETIOTROPIC THERAPEUTIC SCHEMES FOR TREATING PATIENTS WITH NOVEL CORONAVIRUS INFECTION (COVID-19)
by: L. A. Balykova, et al.
Published: (2020-12-01) -
Influenza B Virus: Some Features of Clinical Findings and Etiotropic Treatment
by: O. V. Maltsev, et al.
Published: (2014-09-01) -
Marketing assessment of the potential of the Russian pharmaceutical market in the framework of etiotropic therapy of children with campylobacteriosis
by: D. D. Demchenko, et al.
Published: (2022-07-01) -
STUDY OF LONG-TERM CLINICAL AND PATHOGENETIC EFFECTS OF FAVIPIRAVIR-BASED ANTI-VIRAL DRUG IN PATIENTS WITH METABOLIC SYNDROME IN POST-COVID PERIOD
by: O. A. Radaeva, et al.
Published: (2022-05-01)